These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 21426005

  • 1. Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer Institute.
    Trimble EL, Abrams JS, Ansher SS, Smith MA, Zwiebel JA, Tomaszewski JE.
    Future Med Chem; 2010 Apr; 2(4):555-9. PubMed ID: 21426005
    [No Abstract] [Full Text] [Related]

  • 2. The National Cancer Institute Experimental Therapeutics program.
    Doroshow JH.
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):403-4. PubMed ID: 20733549
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of the National Cancer Institute in drug development.
    Doroshow J.
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract] [Full Text] [Related]

  • 5. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S, Wittes R.
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract] [Full Text] [Related]

  • 6. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G.
    J Natl Cancer Inst; 2010 Feb 03; 102(3):148-51. PubMed ID: 20107160
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A national cancer clinical trials system for targeted therapies.
    Mendelsohn J.
    Sci Transl Med; 2011 Mar 23; 3(75):75cm8. PubMed ID: 21430266
    [Abstract] [Full Text] [Related]

  • 12. More trials, fewer tribulations.
    Eisenstein M.
    Sci Am; 2014 Jul 23; 311(1):S9-11. PubMed ID: 24974700
    [No Abstract] [Full Text] [Related]

  • 13. Developing new agents for the treatment of childhood cancer.
    Kurmasheva R, Morton C, Houghton PJ.
    Curr Opin Investig Drugs; 2005 Dec 23; 6(12):1215-27. PubMed ID: 16372407
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical trials: a recent emphasis in the prevention program of the National Cancer Institute.
    DeWys WD, Greenwald P.
    Semin Oncol; 1983 Sep 23; 10(3):360-4. PubMed ID: 6665563
    [No Abstract] [Full Text] [Related]

  • 17. United States military contributions to the National Cancer Institute.
    Sarvis JA, Thompson IM.
    Urol Oncol; 2009 Sep 23; 27(5):558-61. PubMed ID: 19720303
    [Abstract] [Full Text] [Related]

  • 18. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
    Christian MC, Pluda JM, Ho PT, Arbuck SG, Murgo AJ, Sausville EA.
    Semin Oncol; 1997 Apr 23; 24(2):219-40. PubMed ID: 9129691
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.